Exploring The Biology and Potential Drug Targets of BEND7 (G222389)

Target Name: BEND7

NCBI ID: G222389

BEND7

Exploring The Biology and Potential Drug Targets of BEND7

BEND7 (BEN domain containing 7) is a protein that is expressed in various tissues and organs, including brain, heart, lungs, and gastrointestinal tract. It is a member of the BEN domain family, which is a family of proteins that contain a unique N-terminal region known as the BEN domain. The BEN domain is characterized by a specific amino acid sequence that is conserved across various species, and it is thought to play a role in protein-protein interactions and other cellular processes.

Recent studies have identified BEND7 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential drug targets of BEND7 in more detail.

Biology of BEND7

BEND7 is a 21-kDa protein that is expressed in a variety of tissues and organs, including brain, heart, lungs, and gastrointestinal tract. It is a member of the BEN domain family and is characterized by a unique N-terminal region that is composed of the amino acids Asp-21, Asn-22, Glu-23, Lys-24, Asp-25, Asn-26, and Glu-27.

The BEN domain is conserved across various species and is thought to play a role in protein-protein interactions and other cellular processes. BEND7 has been shown to interact with various proteins, including the protein known as PDGF-R2. This interaction may be important for the function of BEND7, as PDGF-R2 is a known drug target for various diseases, including cancer.

Potential Drug Targets

BEND7 has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One potential mechanism by which BEND7 may be targeted by drugs is through its interaction with PDGF-R2.

PDGF-R2 is a potent protein that is involved in various cellular processes, including cell growth, differentiation, and survival. It has been shown to be a potential drug target for various diseases, including cancer. BEND7 has been shown to interact with PDGF-R2 and may be a target for drugs that are effective in treating these diseases.

Another potential mechanism by which BEND7 may be targeted by drugs is through its role in the development and progression of neurodegenerative diseases. BEND7 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This may be important for understanding the underlying mechanisms of these diseases and for the development of new treatments.

In addition to its potential role in neurodegenerative diseases, BEND7 may also be a target for drugs that are effective in treating autoimmune disorders. BEND7 has been shown to be involved in the development and regulation of immune responses, and it is thought to play a role in the development of autoimmune disorders. This may be important for understanding the underlying mechanisms of autoimmune disorders and for the development of new treatments.

Conclusion

In conclusion, BEND7 is a protein that has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its interaction with PDGF-R2 and its role in the development and progression of these diseases make it a promising target for new treatments. Further research is needed to fully understand the biology of BEND7 and its potential as a drug target.

Protein Name: BEN Domain Containing 7

The "BEND7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BEND7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets